Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford Most Doubt the Trump Administration Will Lower Drug Costs for People Like Them, Though Three-Fourths of Republicans Expect It Will About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds
A study showed that it can help lower blood sugar and insulin levels
These medications can help people who Today, telehealth offers a more convenient way to discuss treatment options for obesity, including the possibility of medication if you meet certain eligibility requirements
Potential Side Effects and Considerations Common side effects of weight loss medications include gastrointestinal symptoms such as nausea, which occurs in about 44% of users, and general symptoms like headache and fatigue
Oral semaglutide (Wegovy pill, Rybelsus) should not be taken while breastfeeding because it contains an absorption enhancer thats known to pass into breast milk
Having cleared the hurdle as a treatment for diabetes, the FDA then approved semaglutide, marketed as Wegovy, for obesity in 2021, and then in Europe the following year
